Axitinib + Ipilimumab in Advanced Melanoma

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT04996823
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ipilimumab — DRUG
    Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses.
  • Axitinib — DRUG
    Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months)

Study Details

The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.

Key Dates

First listed
Aug 9, 2021
Start date
Aug 4, 2021
Status verified
Jul 2026
Primary completion
Aug 20, 2026
Completion
Mar 29, 2027

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ipilimumab + Axtinib
    Participants will receive treatment with ipilimumab 3 mg/kg IV q3 weeks x 4 doses and axitinib at 5 mg by mouth twice daily. Each cycle is 3 weeks/21 days

Primary Outcome Measure

Overall Response Rate [ Time Frame: Up to 24 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Moffitt Cancer CenterTampaFlorida33612-

Find similar trials in Tampa, FL

Nationwide
Melanoma trialsOncology trialsSkin cancer trialsDermatology trials
By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Moffitt Cancer Center· Tampa, FL

Related Studies